Staging and therapy monitoring of multiple myeloma by 99mTc- sestamibi scintigraphy: A five year single center experience

Giuseppe Villa, E. Balleari, M. Carletto, M. Grosso, M. Clavio, A. Piccardo, L. Rebella, L. Tommasi, S. Morbelli, F. Peschiera, M. Gobbi, R. Ghio

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the present study was the evaluation of the diagnostic value of 99mTc-sestamibi (MIBI) in the detection of bone marrow involvement in patients suffering from multiple myeloma (MM) and its possible role in the follow-up. Between 1998 and 2003, 68 patients with MM and 42 pts with monoclonal gammopathy of undetermined significance (MGUS) were consecutively enrolled in this study. 51/68 MM patients had active disease (AD), 11/62 were in complete remission (CR) and 6/68 in partial remission (PR) after chemotherapy. 18 patients with MM repeated a 99mTc-MIBI scintigraphic study at least 2 months after high-dose chemotherapy. All the scans were scored semi quantitatively according to extension and intensity of tracer uptake. All MGUS pts had a negative 99mTc-MIBI. As far as the MM pts are concerned, 54/68 (49%) pts (48 with AD, 5 with PR and 1 with CR) had a positive 99mTc-MIBI scan, while the 99mTc-MIBI scan was negative in 14/68 pts (10 with CR, 1 with PR and 3 with AD). The overall sensitivity of the 99mTc-MIBI scintigraphy was 92%; specificity was 96%. In the follow up of the pts treated with chemotherapy 99mTc-MIBI closely paralleled the activity of myeloma bone disease. In conclusion, these results indicate that 99mTc-MIBI scintigraphy closely reflects myeloma disease activity in the bone marrow, and that a negative 99mTc-MIBI scan in patients with suspected MM clearly, though not absolutely, indicates absence of disease or clinical remission. The results of this study suggest a clear diagnostic value of 99mTc-MIBI scintigraphy in patients with MM and its potential role during the follow-up for the monitoring of MM bone disease.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalJournal of Experimental and Clinical Cancer Research
Volume24
Issue number3
Publication statusPublished - Sep 2005

Keywords

  • TC-sestamibi scintigraphy
  • MGUS
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Staging and therapy monitoring of multiple myeloma by 99mTc- sestamibi scintigraphy: A five year single center experience'. Together they form a unique fingerprint.

Cite this